Xcout Intel
RESONANCE HEALTH LIMITED
Resonance Health Limited is a global provider of healthcare technology and services, specializing in the design, development, and production of software-as-medical devices. The company serves markets across the Asia Pacific, Americas, Europe, Middle East, and Africa. Its portfolio of non-invasive, MRI-based diagnostic tools includes FerriScan, a system for quantifying liver iron concentration (LIC); FerriSmart, leveraging artificial intelligence (AI) for automated, real-time assessment of LIC; HepaFat-AI, an AI-driven solution for real-time, multi-metric liver fat quantification; CardiacT2, which provides dual analysis in conjunction with FerriScan to evaluate cardiac iron accumulation; HepaFat-Scan, a non-invasive MRI method for assessing liver fat within tissue; and LiverSmart, a comprehensive non-invasive MRI device integrating FerriSmart and HepaFat-AI for a unified report. The company further extends its offerings to include quantitative imaging measurements and Contract Research Organization (CRO) services, encompassing rigorous image analysis, imaging charter development, robust project and data management, proactive issue resolution, site tracking with clinical trial progress reports, and streamlined data flow coordination. They also provide comprehensive biomarker services, covering analysis of blood, urine, and protein analytes, alongside RNA, DNA, and genotyping. Their support for multinational and multicenter clinical trials extends to protocol development, subject inclusion/exclusion criteria assessment, dose modification strategies, new therapy safety profile evaluations, and establishing primary and secondary endpoints for drug efficacy. Additionally, they supply phantoms crucial for MRI machine calibration. Its client base includes clinicians, who utilize their solutions for managing human diseases, and pharmaceutical and therapeutic companies engaged in clinical research. Established in 1987, Resonance Health Limited maintains its headquarters in Burswood, Australia.
Subscribe to see RESONANCE HEALTH LIMITED’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
RESONANCE HEALTH LIMITED at a glance
RESONANCE HEALTH LIMITED is a health care equipment & services company headquartered in Burswood, Australia. It is publicly listed (RHT) with a market capitalisation of $18.7M. Xcout tracks 21 named people at RESONANCE HEALTH LIMITED, including Andrew Harrison (Managing Director & CEO).
RESONANCE HEALTH LIMITED leadership
- Andrew HarrisonManaging Director & CEO
- Benjamin CarruthersCFO
- Gavin PintoChief Technology Officer
- Dr. Wenjie Pang, PhDChief Scientific Officer – Imaging & AI
- Chad TondutVice President of Medical Devices
- Dr. Helen PavittVice President of Clinical Trials
15 more named people on record for RESONANCE HEALTH LIMITED, with roles, board committees and tenure — see the full roster →
RESONANCE HEALTH LIMITED competitors
A few of RESONANCE HEALTH LIMITED's closest competitors — see the full list of competitors and alternatives →
Artrya Limited is a medical technology firm that harnesses artificial intelligence (AI) to pinpoint individuals at risk of developing coronary artery disease. The company's key offering is Salix, a cloud-based software application. Salix leverages Artrya's proprietary AI to automate the identification of coronary artery disease through the analysis of coronary computed tomography angiography (CCTA) scans. Founded in 2018, the company is headquartered in West Perth, Australia.
ImExHS Limited delivers cloud-powered medical imaging technologies to customers worldwide, including those in Australia. The firm specializes in the development and sale of modular imaging software systems, which encompass comprehensive information management platforms for disciplines such as radiology, cardiology, and pathology, alongside a robust picture archiving and communication system (PACS). Its principal software solutions include AQUILA for radiology, ALULA for pathology, and Antero for cardiology. Moreover, ImExHS offers STELLA.I, a suite of artificial intelligence tools hosted in the cloud, crafted to bolster diagnostic capabilities for medical professionals. The company further extends outsourced radiology and teleradiology services to hospitals and various other healthcare entities. Established in 2001, ImExHS Limited operates from its base in Mascot, Australia.
CardieX Limited, established in Sydney, Australia, in 1994, is a global innovator specializing in the design, production, and distribution of medical devices for cardiovascular health management. Operating across the Americas, Europe, and the Asia Pacific, the company collaborates with pharmaceutical firms by providing its advanced SphygmoCor XCEL devices. It also delivers comprehensive laboratory and data management services, ensuring high-quality datasets for clinical trial sponsors. Under its CONNEQT brand, CardieX develops cutting-edge home vascular health solutions, which encompass remote patient monitoring, tools for decentralized clinical trials, specialized wearables, and medical applications. A flagship product is the CONNEQT Pulse device, a home-based system that leverages proprietary SphygmoCor technology to precisely measure central blood pressure, arterial waveforms, and other vital arterial health parameters. CardieX serves a diverse clientele, including hospitals, clinics, research institutions, and pharmaceutical companies. The company also maintains a strategic alliance with LifeQ, Inc., focusing on wearable device technology. CardieX Limited was formerly known as AtCor Medical Holdings Limited until its name change in June 2018.
EMVision Medical Devices Limited is an Australian enterprise specializing in the innovation, development, and market introduction of advanced imaging and diagnostic healthcare technologies. The company's principal offering is a compact, mobile brain scanner engineered for the swift detection and continuous tracking of strokes, in addition to fulfilling other medical imaging necessities. Founded in 2017, its operations are headquartered in Macquarie Park.
Optiscan Imaging Limited specializes in the development and market introduction of confocal microscopy technology, applied across both clinical and pre-clinical settings in Australia, Germany, and other global regions. A notable offering is the FIVE2 (ViewnVivo) system, a compact confocal endomicroscope utilized for a broad range of research, including clinical, translational, and pre-clinical studies. Additionally, the company is actively developing the InVivage device, which is intended for use in cancer screening and surgical procedures. Established in 1994, Optiscan Imaging Limited maintains its headquarters in Mulgrave, Australia.
Get RESONANCE HEALTH LIMITED's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on RESONANCE HEALTH LIMITED in Xcout Intel
- 21 named people with titles, LinkedIn and board committees
- The full competitor set, tracking, exports and API access